SCHEMBL7135148

SCHEMBL7135148

CNC(=O)c1ccc2c(c1OC)C(Sc1ccccc1)CS2(=O)=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 1/20 0.37
NUDT1 P36639 2/20 0.33
KAT2B Q92831 1/20 0.32
BAZ2B Q9UIF8 1/20 0.32
HPGD P15428 3/20 0.31
SMN1; SMN2 Q16637 3/20 0.31
ALDH1A1 P00352 3/20 0.31
LMNA P02545 2/20 0.31
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
CHRNB4 P30926 1/20 0.31
CHRNA3 P32297 1/20 0.31
GAA P10253 1/20 0.31
NPC1 O15118 2/20 0.31
RAB9A P51151 2/20 0.31
NFKB1 P19838 1/20 0.31
NFKB2 Q00653 1/20 0.31
RELA Q04206 1/20 0.31
LTB4R Q15722 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7135145 0.89 PLK1 (0.37) PLK1NUDT1KAT2BBAZ2BHPGD
SCHEMBL7130738 0.84 TP53 (0.41) SMN1; SMN2ALDH1A1LMNAKMT2AHTT
SCHEMBL7129940 0.83 ELANE (0.35)
SCHEMBL7131946 0.83 ALDH1A1 (0.39) HPGDALDH1A1LMNAL3MBTL1GAA
SCHEMBL7128968 0.82 CYP1A2 (0.47) HPGDSMN1; SMN2ALDH1A1LMNAMEN1
SCHEMBL7126434 0.78 PLK1 (0.36) PLK1NUDT1KAT2BBAZ2BHPGD
SCHEMBL7124592 0.78 PDPK1 (0.30) SMN1; SMN2NPC1RAB9A
SCHEMBL7130736 0.74 TP53 (0.41) SMN1; SMN2ALDH1A1LMNAKMT2AHTT
SCHEMBL7135332 0.73 ADRA1D (0.35) L3MBTL1
SCHEMBL7131680 0.73 CYP4F2 (0.40) SMN1; SMN2ALDH1A1GAANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6420391-B1 PREVENTION AND/OR TREATMENT OF VARIOUS INFLAMMATORY DISEASES, SEPSIS, MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, OSTEOPOROSIS, CACHEXIA, PSORIASIS, NEPHRITIS, RENAL CELL CARCINOMA, KAPOSI'S SARCOMA, RHEUMATOID ARTHRITIS, GAMMOPATHY, CASTLEMAN'S ONO PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US claimed
EP-1067128-A1 FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-10 EP claimed
US-6555555-B1 Inhibitors of interleukin-6 and/or interleukin-12; for example 4,5-dimethyl-1,1-dioxidebenzo(b)thiophene; treating various inflammatory diseases, autoimmune diseases, cancer, osteoporosis ONO PHARMACEUTICAL CO., LTD. (JP) 2003-04-29 US disclosed
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient KONISHI MIKIO (JP) 2003-04-17 US disclosed
EP-1067128-A1 FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient TPMT, CD47, THPO PLK1 3914/4885NUDT1 2734/4885KAT2B 4361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.